📄 medicine

Long-term quality of life trajectories in Fibrous Dysplasia and McCune-Albright syndrome

This study of 65 adults with Fibrous Dysplasia or McCune-Albright syndrome reveals that while overall health-related quality of life shows mixed stability and decline over a median 7.5-year follow-up, a distinct high-risk subgroup (approximately 30%) experiences severe progressive deterioration that can be identified early by a baseline EQ-5D index score below 0.5.

Original authors: Rohit Vijjhalwar, Franz Clemeno, Melanie A Legrand, Rafael Pinedo-Villanueva, Muhammad Kassim Javaid

Published 2026-07-16

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Rohit Vijjhalwar, Franz Clemeno, Melanie A Legrand, Rafael Pinedo-Villanueva, Muhammad Kassim Javaid

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your body is a bustling city where the buildings are your bones. Usually, these buildings are made of strong, reinforced concrete, designed to last a lifetime. But for some people, a tiny glitch in their genetic blueprint causes some of those buildings to be constructed out of soft, spongy clay instead. This condition is called Fibrous Dysplasia (FD). In a few cases, this glitch also causes other parts of the city to go haywire, like the power grid or the water supply, leading to a more complex version of the condition called McCune-Albright syndrome (MAS). Because these are rare and tricky conditions, doctors have known for a long time that they cause pain and make daily life harder, but they've mostly been looking at snapshots of the problem. They knew the city had some crumbling buildings, but they didn't have a time-lapse video to see how the city changed over the next decade.

To understand how these patients are really doing, researchers need to track something called "Health-Related Quality of Life" (HRQoL). Think of this not as a medical test, but as a daily diary where people rate their own happiness, how easily they can walk, if they can take care of themselves, and how much pain or worry they feel. While we know these patients often struggle, we haven't really known if their lives get steadily worse, stay the same, or perhaps even get better with time. This is the big question: Does the city slowly crumble, or do some neighborhoods actually find a way to stabilize?

This study decided to find out by looking at a long-term video of 65 adults with FD or MAS. The researchers used a special tool called the EQ-5D, which is like a simple, five-question survey that asks people to rate their mobility, self-care, daily activities, pain, and anxiety, plus a big thermometer-style score for their overall health. They gathered data from a UK research database called RUDY, where patients volunteered to fill out these surveys every six months for an average of 7.5 years. That's a lot of data points—500 in total—allowing the team to watch the story unfold over time rather than just guessing from a single moment.

The story the data told was a mix of good news and a warning. When they looked at the group as a whole, they found a slow, steady decline in certain areas. Over the years, people reported getting slightly worse at moving around, taking care of themselves, and managing their anxiety or depression. Their overall health thermometer scores also dropped a little bit each year. Interestingly, their pain levels and ability to do usual activities didn't seem to get significantly worse or better; they just stayed about the same. It's as if the city's traffic and noise levels remained constant, but the parks and the residents' mood slowly faded.

However, the real plot twist came when the researchers stopped looking at the "average" person and started looking at individual stories. They used a computer method called "clustering" to sort the patients into two distinct groups based on how their health changed. They discovered that the patients weren't all on the same path. About 70% of the people formed a "Stable Majority" group. These folks started with a decent quality of life and stayed pretty much the same, or even got slightly better, over the 7.5 years.

The other group, making up about 30% of the patients, was a "High-Risk Decliner" group. This was the dramatic part of the story. These patients started with a very poor quality of life (their health score was already quite low at the beginning) and then took a sharp dive, getting significantly worse over time. The researchers found that the single best way to spot who belonged in this "High-Risk" group was to look at their very first survey. If a patient started with a low score, they were very likely to be the ones whose lives deteriorated. Surprisingly, it didn't matter if they were a boy or a girl, how old they were, or exactly which type of FD or MAS they had. The starting point of their quality of life was the crystal ball that predicted the future.

So, what does this mean? The study suggests that while the average person with this condition might see a slow, gentle decline in their daily functioning and mood, there is a specific subgroup of about one in three patients who are on a much steeper, more dangerous slide. The paper argues that doctors shouldn't just wait and see; they should use that first quality-of-life survey as a warning light. If a patient starts with a low score, they might need extra help, like physical therapy or mental health support, right away to try to stop the slide. The study doesn't prove a cure or a fix, but it does offer a map, showing that not all journeys are the same and that early detection of the "decliners" could be the key to helping them stay on a better path.

Technical Summary: Long-term Quality of Life Trajectories in Fibrous Dysplasia and McCune-Albright Syndrome

Problem Statement
Fibrous Dysplasia (FD) and McCune-Albright Syndrome (MAS) are rare, mosaic bone disorders caused by somatic GNAS mutations, leading to constitutive Gs signaling, dysregulated cAMP production, and the replacement of healthy bone with fibro-osseous tissue. While the molecular basis and clinical manifestations (pain, deformity, fractures, endocrinopathies) are understood, long-term patient-reported outcomes remain poorly characterized. Existing literature relies heavily on cross-sectional analyses, which document reduced quality of life (QoL) compared to the general population but fail to capture how health-related quality of life (HRQoL) evolves over time or to identify distinct subgroups within this heterogeneous population. There is a critical evidence gap regarding the longitudinal natural history of HRQoL in FD/MAS, which is necessary to inform shared decision-making, supportive care, and health economic evaluations.

Methodology
This study utilized a longitudinal cohort design based on data from the RUDY (Rare and Undiagnosed Diseases Study) research platform, a UK-based online database for rare diseases.

Cohort: 65 adults with self-reported FD/MAS diagnoses were included, contributing 500 EQ-5D-5L observations over a median follow-up of 7.5 years (IQR 4.0–9.0).
Instrument: HRQoL was assessed using the EQ-5D-5L, covering five domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a Visual Analogue Scale (EQ-VAS). Index scores were calculated using the NICE-recommended crosswalk algorithm.
Longitudinal Modeling: Linear mixed-effects models were employed to estimate annual changes in EQ-5D domains and VAS scores, adjusting for age, sex, and the calendar year of entry. Random intercepts accounted for within-person correlation.
Trajectory Classification: To identify clinically meaningful subgroups, unsupervised clustering (K-means, $k=2$ ) was performed on the change in EQ-5D index scores from baseline to last follow-up. This approach was validated using Gaussian Mixture Modelling (GMM) and Bayesian Information Criterion (BIC).
Statistical Analysis: Baseline associations with cluster membership were tested using Fisher's exact tests and t-tests. Sensitivity analyses addressed follow-up duration, reporting bias, and interaction effects.

Key Results

Population-Level Trajectories: Adjusted models revealed a significant annual worsening in specific domains: mobility ( $+0.029$ steps/year), self-care ( $+0.03$ steps/year), and anxiety/depression ( $+0.03$ steps/year). EQ-VAS scores declined by 0.5 points annually. Conversely, pain/discomfort and usual activities remained stable over time.
Heterogeneity in Outcomes: While the population showed a modest tendency toward decline, individual trajectories were highly heterogeneous. Approximately 36.9% of participants experienced clinically meaningful deterioration (index decrease $>0.05$ ), 32.3% improved, and 30.7% remained stable.
Distinct Trajectory Subgroups: Clustering identified two distinct groups:
1. High-risk "Decliner" Group (~31%): Characterized by poor baseline HRQoL (mean EQ-5D index 0.33) and marked deterioration over time (mean change $-0.23$).
2. Stable Majority Group (~69%): Characterized by moderate baseline HRQoL (mean index 0.72) and relative stability or slight improvement (mean change $+0.02$ ).
Predictors of Trajectory: Baseline EQ-5D index scores were the strongest predictor of cluster membership ( $p < 0.001$ ). Specifically, a baseline index $< 0.5$ was strongly associated with the high-risk decliner group. Age, sex, and specific FD/MAS subtypes (monostotic, polyostotic, MAS) showed no significant association with trajectory group membership.

Significance and Claims
The paper claims that FD/MAS patients exhibit distinct long-term HRQoL trajectories that cannot be fully explained by demographic factors or disease subtypes alone.

Risk Stratification: The study posits that baseline patient-reported health status (specifically the EQ-5D index) serves as a practical, early risk stratification tool. Patients presenting with a low baseline index are at significant risk for progressive, severe decline.
Clinical Utility: Early recognition of these high-risk trajectories can support the implementation of personalized monitoring and multidisciplinary interventions, such as physical rehabilitation and psychosocial support, tailored to those most likely to deteriorate.
Health Economics and Trials: The findings challenge the assumption of static or uniformly declining utility values in economic models. By demonstrating heterogeneous trajectories with a specific subgroup experiencing marked deterioration, the authors argue for the incorporation of trajectory-based utility estimates into cost-effectiveness analyses and the inclusion of these distinct subgroups in future clinical trials.
Limitations: The authors acknowledge limitations including reliance on self-reported diagnosis without radiological validation, the potential for selection bias inherent in online recruitment (digital literacy), and the generic nature of the EQ-5D instrument, which may not fully capture disease-specific nuances like endocrinopathies or episodic pain patterns.

In conclusion, the study provides the first longitudinal characterization of HRQoL in FD/MAS, highlighting that while the disease burden is progressive for a substantial subgroup, this decline is identifiable at the first assessment through generic health metrics, offering a pathway for targeted clinical management.

Technical Summary: Long-term Quality of Life Trajectories in Fibrous Dysplasia and McCune-Albright Syndrome

More like this